Northwest (NWBO) Moves Sideways: Will It Jump Again?

Biotech stocks frequently depend on corporate updates and rarely move organically. Northwest stock isn’t an exception here. DCVax clinical trials have made NWBO trending among small-cap biotech stocks.

Two months ago the company released a presentation about the phase 3 clinical trial of the candidate for treating glioblastoma online. After seeing some positive results newcomers started buying the stock throughout the week. However, after surging to $1.91 NWBO drastically decreased to $0.76.

This week the stock is moving between $0.68 and $0.65. If any updates from DCVax clinical trials come out NWBO will surely move drastically either down or up. It would be the best idea to observe the stock on daily basis.

nwbo stock